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Objectives: To evaluate the therapeutic outcome of ultrasound-guided intralesional injection of bleomycin A5 on
treatment of venous malformation (VM) in cervical-facial region.
Methods: Seventy-five patients (32 male, 43 female), ranging in age from 13 to 60 years old, suffering from VM in
cervical-facial region were admitted to and treated at our hospital between June 2006 and February 2007. Of all the
patients, 54 malformations were located in the facial region, eight in the submental region, 10 in the submandible region,
and three in the cervical region; all were treated by ultrasound-guided intralesional injections of bleomycin A5. The size
of the lesions ranged from 6 9mm to 32 39mm. Injection of bleomycin A5 on venous malformation was then carried
out through the inspection of ultrasonography. Repeated course of bleomycin A5 injection was administrated for larger
malformations. The amount was 8 mg each time. The therapeutic interval was two to four weeks. The therapeutic
outcome on venous malformation was evaluated by physical examination and ultrasonography with Doppler according to
the Shou standards, including four grades; cured, basically cured, improved, and invalid. The complications were also
observed during and after injection.
Results: The duration of follow-up ranged from 6 to 24 months. The average times of treatment were 1.64 times. Among
them, 42 patients (56%) received only one time of treatment, 21 (28%) patients received two times, nine (12%) patients
received three times, and three (4%) patients received four times. According to criteria of therapeutic outcome, the results
showed cured in 63 patients (84%), basically cured in 10 patients (13.33%), improved in two patients (2.67%), and none
ineffective. Seventy-one patients (94.67%) had local swelling in injection region for several days and two patients (2.67%)
developed temporary dizziness after treatment. There were no other complications recorded.
Conclusions: Intralesional injection of bleomycin A5 establishes a promisingly effect way for patients suffering from VM
in the cervical-facial region under ultrasound guidance. (J Vasc Surg 2010;51:940-5.)Venous malformations (VMs) are one type of vascular
malformation formerly referred to as “cavernous hemangi-
omas.” They are also the most common vascular anomalies
in the cervical-facial region, which usually involve multiple
anatomical regions including the skin, mucosa, and critical
neuromuscular structures. If left untreated, it will increase
gradually and finally affect appearance and organ functions.
Intraoral VMs can bleed, distort dentition, cause speech
problems, or even obstruct the upper airway, thus increas-
ing the difficulty of treatment.
A variety of techniques have been used in the treatment
of VMs. The main therapies include laser therapy, surgical
excision, and sclerotherapy. Laser therapy is effective for
small superfacial VMs. When it is sometimes used for deep
lesions, skin flap elevation is required.1,2 Complete surgical
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940resection is often difficult and often involves massive bleed-
ing, severe scars, and injury of the facial nerves. Sclerother-
apy is an optional approach for treating this disease. The
main advantages are no external scarring and few compli-
cations as compared with surgical treatment. Therefore,
sclerotherapy is selected as the first choice for VMs in the
face and neck.3-6
There have been attempts to use many sclerosants,
including sodium morrhuate, absolute ethanol, and bleo-
mycin. All these sclerosing agents have their particular
advantages and limitations.3-6 Sodium morrhuate can pro-
mote thrombosis and occlude the vascular venous vessels in
the lesions; however, it might cause complications such as
ulceration and hematuria if a high dose is injected. Al-
though absolute alcohol is widely used in the treatment of
large VMs because of its low cost, antiseptic quality, wide
availability, and ease of use, ethanol sclerotherapy may
result in a wide range of complications, mainly severe pain
immediately after injection, skin necrosis, neuropathy, and
facial nerve injury.
Bleomycin is a glycopeptide antibiotic produced by the
bacterium Streptomyces verticillus. Usually, it is used as an
antineoplastic drug to treat many kinds of cancer, such as
lymphoma, cervical cancer, head and neck cancer, and
testicular cancer. Bleomycin A5, also named pingyangmy-
cin, is the most commonly used sclerosing agent for the
treatment of vascular anomalies in China. Histological in-
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detachment of endothelial cells and lead to narrowing or
occlusion of the vessels.7 Compared with sodium mor-
rhuate and absolute ethanol, bleomycin A5 will not result
in ulceration and necrosis in skin and mucosa. There are
also no reports on hematuria and neuropathy. In addition,
bleomycin A5 sclerotherapy has no great pain or nerve
injury, which makes it especially suitable for treating VMs
in the cervical-facial region. Therefore, intralesional injec-
tion of bleomycin A5 on VMs in cervical-facial region has
been a routine therapy and has proven to be effective3,5,7-11
in China.
However, traditional direct percutaneous treatment
through aspiration of the blood could not really confirm
the needle tip within the lesions. It still has a risk of
complications, including intravascular injection, and is in-
capable of treating some lesions in deep tissues. Also, it is
sometimes difficult to orientate the needle into the lesion.
Therefore, it is necessary to look for other, more effective
methods with relatively minimal side effects.
Ultrasonography with Doppler is an effective diagnos-
tic tool to rate the blood stream. It allows an unambiguous
classification as to venous, arterial, or lymphatic malforma-
tion,12 which is a simple noninvasive method to distinguish
slow-flow from fast-flow vascular malformation. Therefore,
if ultrasound guidance technique is used in the treatment of
VMs, the outcome might improve.
In this study, we present our experience and clinical
outcome in treating 75 patients suffering from VMs in
cervical-facial region with bleomycin A5 through ultrasound-
guided intralesional injection.
PATIENTS AND METHODS
Patients admitted to our hospital were those with VMs
in cervical-facial region. Patients chosen for bleomycin A5
treatment are non-allergic to the bleomycin A5 in the past
and with no systematic disease. Each of them had small to
middle sized VMs, and there was no drainage venuous from
the lesion or the drainage venuous was less and their
diameters were smaller by ultrasonography. Therefore,
these VMs belonged to type I and type II lesions13,14
according to Puig’s classification system of VMs, which
based on anatomical and hemodynamic features (Table).
There were 75 VMs patients treated at our hospital
between June 2006 and February 2007. Thirty-two were
male, while 43 were female, ranging in age from 13 to 60
years old. Diagnosis was confirmed by history, clinical
presentations, physical examination, and ultrasonography
Table. Puig’s classification scheme
Type
I Isolated malformation without peripheral drainage
II Malformation that drains into normal veins
III Malformation that drains into dilated veins
IV Malformation that represents dysplastic venous ectasiawith Doppler (GE Logiq 400 CL PRO, Milwaukee, Wisc).Of all the patients, 54 malformations (72%) were located in
the facial region, including 32 (42.67%) in parotid region,
four (5.33%) in orbital area, 16 (21.33%) in nasal-labial
area, and two (2.67%) in frontotemporal area. The others
involved eight (10.67%) in the submental region, 10
(13.33%) in the submandible region, and three (4%) in the
cervical region. The lesion was measured clinically and con-
firmed by ultrasonography, with a maximum of 32 39 mm,
and a minimum of 6 9 mm.
The powder of bleomycin A5 (TianjinTaihe Pharma-
ceutical Co. Ltd, Tianjin, China), 8 mg in dose, was dis-
solved by solution containing dexamethasone (5 mg, 1 mL;
Shanghaitongyong Pharmaceutical Co. Ltd, Shanghai,
China) and lidocaine 2% (4 mL; Beijingzizhu Pharmaceu-
tical Co. Ltd, Beijing, China). If the size of malformations
was less than 10  15 mm by ultrasonography, dexameth-
asone and lidocaine were reduced to half dose, while the
injected bleomycin A5 dose remained 8 mg each time.
Before treatment, each patient underwent intramuscu-
lar injection of promethazine hydrochloride, an antiallergic
drug, to prevent hypersensitivity. First, the lesion was again
confirmed by ultrasonography. The suitable puncture path-
way was also determined through multiple scanning. Then,
a puncture needle was pricked into lesions under ultra-
sound guidance. After multiple scanning and the aspiration
of the blood confirmed its intralesional position, the injec-
tion of bleomycin A5, filled in the externally connected
syringe, was carried out through the inspection of ultra-
sonography. A multi-point injection was used so as to
uniformly distribute bleomycin A5 in the lesion area. At
last, the surrounding region of malformations and the
injection pinhole were pressed for three to five minutes in
order to prevent spilling or bleeding. Repeated course of
bleomycin A5 injection was administrated for larger mal-
formations. The therapeutic interval was two to four weeks.
All patients were monitored for vital signs and symp-
toms, general examination of blood, hepatic, and renal
function tests, and chest X-ray during the course of their
treatment. The therapeutic effect on VMs was evaluated by
physical examination and ultrasonography with Doppler
according to the Weidong Shou standards.8
Cured. Lesions disappear completely and the color of
skin and mucosa are normal without functional distur-
bance. No recurrence has been observed on follow-up visit.
Basically cured. Lesions disappear basically. The color
of skin and mucosa are normal or pigmentary lightly with-
out functional disturbance. The appearance is asymmetrical
and the patient needs observing.
Improved. The reduction of lesions is more than 50%,
but the lesion did not disappear completely and needed
other treatment or plastic surgery.
Invalid. The reduction of lesions is less than 50% after
three to five times treatment.
All patients were observed for development of any local
side effects (such as hyperemia, edema, pain, ulceration,
and effusion in the injection region and surrounding tissue)
or general side effects (such as fever, gastrointestinal reac-
n was
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sensitiveness) during and after injection.
RESULTS
All 75 patients completed the treatment and achieve
the ideal effect. The follow-up range was 6 to 24 months,
and the mean follow-up time was 10.3 months. The aver-
age times of treatment were 1.64 times. Among them, 42
patients (56%) received only one time of treatment, 21
(28%) patients received two times, nine (12%) patients
received three times, and three (4%) patients received four
times. According to the follow-up visit, 84% (63 patients)
were cured, 13.33% (10 patients) were basically cured,
2.67% (two patients) were improved, and 0% were ineffec-
tive.
Seventy-one patients (94.67%) had local swelling in
injection regions but the swelling disappeared after three to
five days without any special treatment. Two patients
(2.67%) had momentary dizziness after treatment and felt
better in 30 minutes.
There were no other local reactions and general reac-
tions found during and after the treatment.
Typical case. Male, 14 years old, with a clinical diag-
nosis of VMs in left parotideomasseteric region. The first
visit was on Aug. 10, 2006. The lesion is 37.8 20.3 mm,
confirmed by ultrasonography (Fig 1). Injection of bleo-
mycin A5 (8 mg) on VMs was carried out under ultrasound
guidance. On Aug. 24, 2006, the lesion reduced to 22.5 
10.0 mm (Fig 2) and the patient was given the second
treatment; on Oct. 8, 2006, the lesion reduced to 14.5 
8.3 mm (Fig 3) and the patient was given the third treat-
ment. The lesion disappeared after three sessions, and the
color of skin was normal without functional disturbance.
No recurrence has been observed on follow-up visit on Jul.
Fig 1. The ultrasonography image showed the lesio25, 2007 (Fig 4).DISCUSSION
The mechanism of bleomycin A5 on VMs is its injury to
endothelial cells and occlusion of the vessels. After proper
injections, the fibrous degenerated gradually and the le-
sions are under regression without necrosis and obvious
scar. This minimally invasive treatment is easy to carry out and
has an affirmatory effect. Therefore, it has an extensive appli-
cation in clinics in China from the 1990s to now.3,5,7-11
Zheng et al reviewed 3824 patients suffering from heman-
giomas and VMs in cervical-facial region who underwent
bleomycin A5 treatment in 31 reports published from 1991
to 2003 in China.9 However, only 1335 patients were
evaluated on therapeutic effect because both VMs and
hemangiomas patients were included, as bleomycin A5 also
has a therapeutic effect on hemangiomas.7,11 In addition,
there were also some reports using different classifications.
Among them, 932 patients (69.81%) were cured, 263
patients (10.70%) were basically cured, 103 (7.72%) pa-
tients were improved, and 37 patients (2.77%) were inef-
fective. The effective rate was 97.23%.
However, single injection of bleomycin A5 without
ultrasound guidance has been faced with many problems.
The routine percutaneous treatment will make the drug
disperse into surrounding tissues so that the drug concen-
tration in lesion area will decrease significantly, which re-
duces the therapeutic effect. In addition, a lot of VMs in
clinic are in deep region, adjacent to many important tissues
such as parotid gland, facial nerve, and cervical vessels.
Usually, the intralesional injection is based on clinical ex-
amination and injection into the lesion with aspiration of
blood, which has a high risk, especially in treating lesions in
deep regions. Sometimes misjudgement may lead to side
effects and intravascular injection will result in serious com-
37.8  20.3 mm at the first visit on Aug. 10, 2006.plication. Therefore, Yamaki15 first treated seven patients
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of absolute alcohol under ultrasound guidance. Yamaki has
researched this method in depth and reports many advan-
tages of it. For example, it will prevent intra-arterial injec-
tion accidents.15-17
Bleomycin A5 has also been used to treat VMs in
cervical-facial region for more than 10 years in our hospi-
tal.5,7 We found there were some factors that affect the
Fig 2. The ultrasonography image showed the lesion w
on Aug. 24, 2006.
Fig 3. The ultrasonography image showed the lesion wa
on Oct. 8, 2006.outcomes; for example, the size and location of the malfor-mations, the number and the diameter of the drainage
venuous, different treatment schemes, and whether there
was ultrasound guidance. In this study, we evaluated the
therapeutic outcome of injection of bleomycin A5 on treat-
ment of venous malformation in cervical-facial region. The
malformations were small to middle sized which had no
drainage venuous or the drainage venuous was less and
their diameters were smaller by ultrasonography. One or
.5  10.0 mm after the first injection of pingyangmycin
5 8.3 mm after the second injection of pingyangmycinas 22s 14.multiple times of injection of 8 mg bleomycin A5 in dose
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of ultrasonography with therapeutic intervals of two to four
weeks.
Through ultrasonic inspection, the range of lesions, the
tissue plane occupied, and the relationship between lesions
and surrounding tissues could be determined so that the
effects of treatment could be improved by ensuring the precise
injection position. After the follow-up visit, the results
showed each grade of the therapeutic effect was improved
comparing with the review results of Zheng,9 which were
84% cured, 13.33% basically cured, 2.67% improved, and
none ineffective. The effective rate reached 100%, which
was also improved compared with the previous re-
sults3,5,7,10-11,13-14 by routine treatment.
Considering the treatment times, the review of Zheng9
showed that there were 302 patients who received one time
of treatment, 266 patients received two times, a few re-
ceived seven to eight times, and one even received 17 times,
according to the reports that had such treatment time
statistics. In this study, 63 patients (84%) received only one
or two times of treatment, which suggests that on the one
hand, the treatment time could be reduced under ultra-
sound guidance; on the other hand, the patients only
suffered from VMs, and perhaps the sizes of VMs in this
study were relatively smaller compared with others in
former reports.
Considering the complications recorded, the review of
Zheng9 showed that of all the 3824 patients, two patients
had anaphylactic shock (0.005%), 232 patients had fever
(6.07%), 171 patients had gastrointestinal reactions (4.47%),
62 patients had local ulceration (1.62%), three patients had
local cutaneous reaction (0.008%), and none had pulmo-
Fig 4. The ultrasonography image showed the lesion dis
(Jul. 25, 2007).nary fibrosis. While under ultrasound guidance, the treat-ment complications were reduced. For example, Yamaki16
reported only swelling (75%) and local pain (82%) after
treatment of patients with VMs in cervical-facial region by
intralesional injection of absolute alcohol, though he had
not used bleomycin A5, and these complications disap-
peared five to seven days later. Although the chances for
complications may be raised in local tissue when bleomycin
A5 is put in the wrong place with high dose, we observed
that only transient local swelling (94.67%) and momentary
dizziness (2.67%) were present in this study, as experienced
doctors performed the whole operation under ultrasound
guidance (R.H., J.G., Y.Y.).
These encouraging results were mainly relevant with
the precise injection of bleomycin A5 into lesions under
ultrasound guidance, which made the drug concentrations
centralize in lesion areas so as to improve the therapeutic
effect and reduce the complications. Moreover, the re-
duced complications were also relevant with the use of
dexamethasone and the antiallergic drug before treatment.
We have not mentioned the lesion recurrence in the study,
for it may be associated with the fact that most lesions were
relatively small and the time of follow-up interval was
relatively short.
However, there are some weaknesses in this study.
First, there was no control group in this report. We only did
a retrospective study, not a prospective one. Second, there
was a lack of the authors being blinded to the results.
Therefore, a controlled, blinded study should be recom-
mended in the future.
Although ultrasonic inspection was used each time,
several advantages of this special treatment were found.
First, the therapeutic effect was improved. The final results
ared completely on follow-up visit nearly 10 months laterappecould suggest that the efficiency of utilizing bleomycin A5
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the treatment is safe. It has the ability to prevent the injury
on the important tissues through the pricking path, which
not only reduces the occurrence of complications but also
enlarges the routine treatment range. Third, the treatment
is minimally invasive compared with surgery. The applica-
tion of this technique establishes a promisingly effect way
for patients suffering from VMs.
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